Fraud Investigation: Levi & Korsinsky Investigates Aldeyra Therapeutics, Inc. (ALDX) on Behalf of Shareholders

Impact · against what's priced in

Aldeyra Therapeutics faces a severe valuation hit following an FDA Complete Response Letter citing insufficient efficacy for its lead drug, reproxalap, compounded by a new securities fraud investigation. Other companies mentioned (OCS, ENSG, SAIL) face separate, less detailed legal investigations that introduce additional regulatory and financial risk.

ALDX−1.00

No priced-in read yet